SLS-007 (peptidic inhibitor)

SLS-007 is a Peptide-based Approach Targeting the NACore for Parkinson’s Disease

SLS-007 is a family of rationally-designed peptidic inhibitors which target the NACore (non-amyloid component core) of alpha-synuclein (α-synuclein) to inhibit protein aggregation in patients with Parkinson's Disease (PD)

The overexpression of α-synuclein leads to the formation of α-synuclein aggregates which comprise Lewy bodies and neurites which are the hallmarks of the pathogenesis of PD

Recent in vitro and cell culture research have shown that SLS-007 has the potential to stop the propagation and seeding of α-synuclein aggregates

Seelos will evaluate in vivo delivery of SLS-007 in a PD transgenic mouse model

The goal will be to establish in vivo pharmacokinetics and pharmacodynamics profiles and target engagement parameters of SLS-007

About α-synuclein

The α-synuclein protein function in the healthy brain is currently unknown

It is of great interest to PD researchers because it is a major constituent of Lewy bodies, protein clumps that are the pathological hallmark of PD

In the several years since its discovery, α-synuclein has been the focus of intensive efforts by basic PD researchers working to definitively characterize the protein's role in PD and its potential as a target for neuroprotective therapies